U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07428486) titled 'A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia' on Feb. 19.
Brief Summary: To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.
Study Start Date: Aug. 17, 2026
Study Type: INTERVENTIONAL
Condition:
Phase I
FLAG Chemotherapy
Lisaftoclax
Pelcitoclax
Relapsed/Refractory
Lymphoblastic Leukemia Acute
Intervention:
DRUG: Fludarabine
Given by IV
DRUG: Cytarabine
Given by IV
DRUG: G-CSF
Given by Injection
DRUG: Lisaftoclax
Give...